GlassScriptPhysician profile
David J Burkey
NPI 1669432886
$9,719.09
in general payments reported to CMS, 2019-2025
40 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,217 · 2020: $1,611 · 2021: $1,176 · 2022: $1,348 · 2023: $948 · 2024: $639 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,132.92 | 2019-2025 | |
| Boston Scientific Corporation | $1,082.14 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Farapulse |
| Janssen Pharmaceuticals, INC | $793.21 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $775.32 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $714.28 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $645.52 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $621.46 | 2019-2025 | Farxiga |
| Abbott Laboratories | $567.94 | 2019-2025 | Confirm Rx, Jot Dx, Optisense |
| Amgen INC. | $455.39 | 2019-2023 | Repatha |
| Biotronik INC. | $319.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.39 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $226.11 | 2021-2022 | |
| Esperion Therapeutics, INC. | $212.64 | 2020-2021 | |
| Cvrx, INC. | $162.14 | 2023 | Barostim Neo System |
| Portola Pharmaceuticals, LLC | $142.33 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Burkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.